Pipeline
Pipeline
Pipeline
Powered by the Q²TCE platform, Qymune is building a growing pipeline through internal innovation and external partnerships, targeting autoimmune diseases and oncology with a focus on solid tumors.
Powered by the Q²TCE platform, Qymune is building a growing pipeline through internal innovation and external partnerships, targeting autoimmune diseases and oncology with a focus on solid tumors.
Powered by the Q²TCE platform, Qymune is building a growing pipeline through internal innovation and external partnerships, targeting autoimmune diseases and oncology with a focus on solid tumors.
Pipeline: Driven by Both Internal Innovation And External Partnerships
Pipeline: Driven by Both Internal Innovation And External Partnerships
Pipeline: Driven by Both Internal Innovation And External Partnerships
Asset
Indication
Target
Lead Identification
Optimization
IND enabling
QYM1
QYM1
QYM1
Autoimmune diseases (RA,MG), B cell lymphoma
Autoimmune diseases (RA,MG), B cell lymphoma
Autoimmune diseases (RA,MG), B cell lymphoma
Indication
CD19 x Q²TCE
CD19 x Q²TCE
CD19 x Q²TCE
Target
Lead
identification
Optimization
QUM2
collaboarion Program1
Small Cell Lung Cancer (SCLC)
Indication
Undisclosed Q²TCE
Target
Lead
identification
Optimization
RQ
collaboarion Program2
Heapatocellular carcinoma (HCC)
Indication
Undisclosed Q²TCE
Target
Lead
identification
Optimization
QUM3
Prostate Cancer
Indication
Undisclosed Q²TCE
Target
Lead
identification
Optimization
QUM4
Acute Myeloid Leukemia(AML)
Indication
Undisclosed Q²TCE
Target
Lead
identification
Optimization
QUM5
collaboarion Program3
Undisclosed
Indication
Undisclosed Q²TCE
Target
collaboarion Program3
Lead
identification
Optimization
QYM2
collaboarion Program1
QYM2
collaboarion Program1
Small Cell Lung Cancer (SCLC)
Small Cell Lung Cancer (SCLC)
Undisclosed Q²TCE
Undisclosed Q²TCE
RQ
collaboarion Program2
RQ
collaboarion Program2
Hepatocellular carcinoma(HCC)
Hepatocellular carcinoma(HCC)
Undisclosed Q²TCE
Undisclosed Q²TCE
QYM3
QYM3
Prostate Cancer
Prostate Cancer
Undisclosed Q²TCE
Undisclosed Q²TCE
QYM4
QYM4
Acute Myeloid Leukemia(AML)
Acute Myeloid Leukemia(AML)
Undisclosed Q²TCE
Undisclosed Q²TCE
collaboarion Program3
Undisclosed
Undisclosed
Undisclosed Q²TCE
Undisclosed Q²TCE
